E-mail conversation about this 5-4-12
2015-01-13azim58 - E-mail conversation about this 5-4-12
Kurt Whittemore <[email protected]>
Wed, May 2, 2012 at 4:29 PM
To: [email protected]
Hi 5Prime representative,
Do you sell an E. coli affinity resin in order to pre-clear antibody
containing serum of e. coli specific antibodies?
According to a paper with the title of "Serologic analysis of ovarian
tumor antigens reveals a bias toward antigens encoded on 17q" it looks
like you do, but I did not see such a product on your website. I may have
missed it.
Quote from paper: "Prior to screening, serum from stage III/IV ovarian
cancer patients was precleared of Escherichia coli-specific antibodies
using an E. coli affinity resin (5Prime-3Prime) according to the
manufacturer’s instructions (Eppendorf, Hamburg, Germany)."
Thanks for any help and information you can offer me!
Best regards,
Kurt Whittemore
Graduate Student
Arizona State University
BIODESIGN INSTITUTE
Center for Innovations in Medicine
1001 S McALLISTER AVE
TEMPE, AZ 85287
===========================================================================
NA TechService <[email protected]>
Fri, May 4, 2012 at 6:34 AM
To: "[email protected]" <[email protected]>
Dear Kurt Whittemore,
Thank you for your request.
Unfortunately, we don't offer this product.
To my knowledge the company 5PRIME- 3PRIME has been taken over by
Eppendorf a long time ago. They offer some of the 5PRIME- 3PRIME products
but not the whole portfolio.
Later 5 PRIME took over these product portfolio from Eppendorf, but as
mentioned before we don't offer this product.
Please let me know if you have any further questions.
Kind regards,
Nicole Seier
Have you heard of our new Customer Reward Program 5 PRIMEstars?
Visit www.my5PRIME.com to register and receive your 3000 5 PRIMEstars
welcome bonus today.
Dr. Nicole Seier
¦ Technical Service Specialist¦5 PRIME GmbH¦ www.5PRIME.com
5PRIME Customer Service: 866-344-0699 ¦ [email protected] PRIME
GmbH, Hamburg
Commercial Register Hamburg (HRB100299)
Managing Directors: Benedikt von Braunmühl, Axel Backheuer
This communication may contain confidential and/or privileged
information. If you are not the intended recipient, please return this
message to the sender, and delete all copies thereof without disclosing
or using the information herein